/
INBX
$95.50+$0.69 (+0.73%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.4B
15M shares
52-week range
$13.97 – $155.29
58% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$67.98
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $9.1M | $12.8M | $7.1M | $2.2M | $1.8M | $200.0K | $1.3M |
| Cost of revenue | $33.5M | $47.9M | $73.5M | $2.7M | $110.2M | $1.2M | $2.3M | $2.5M |
| Gross profit | −$26.0M | −$38.8M | −$60.7M | $4.4M | −$108.0M | $609.0K | −$2.1M | −$1.2M |
| Gross margin | -346.1% | -426.9% | -473.8% | 62.3% | -4926.7% | 33.8% | -1042.5% | -91.0% |
| R&D | $33.5M | $47.9M | $73.5M | $71.4M | $110.2M | $190.6M | $203.7M | $113.0M |
| Operating income | −$29.5M | −$43.7M | −$67.4M | −$76.6M | −$129.1M | −$219.2M | −$331.4M | −$135.0M |
| EBITDA | −$28.8M | −$42.6M | −$63.8M | −$75.4M | −$125.8M | −$206.7M | $1.70B | −$132.5M |
| Net income | −$31.2M | −$51.4M | −$75.6M | −$81.8M | −$145.2M | −$241.4M | $1.69B | −$140.1M |
| Net margin | -415.5% | -565.3% | -590.5% | -1147.6% | -6625.3% | -13408.9% | 843786.0% | -10773.5% |
| EPS (diluted) | -1.15 | -1.41 | -2.99 | -2.15 | -3.62 | -5.12 | 116.58 | -9.04 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4M | $-9.23 | $-11.84–$-6.63 | 1 |
| 2027 | $57M | $-6.53 | $-8.37–$-4.69 | 1 |
| 2028 | $131M | $-3.98 | $-5.10–$-2.85 | 1 |
| 2029 | $203M | $-2.73 | $-3.50–$-1.96 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.72
Price
$95.50
Implied downside
-99%
Peer comparison
Inhibrx Biosciences, Inc. Common Stock
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
www.inhibrx.com- Employees
- 110
- IPO / List date
- May 28, 2024
- HQ
- LA JOLLA, CA
Held by traders on TradeandTell
No one on the platform currently holds INBX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 50,183 | $3.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded INBX yet.
